Replies to post #246342 on Biotech Values

[Doc328]

There would be fewer visits. Patients on toxin therapies generally see us at each injection visit and only in between visits if something new is up. As an example my migraine Botox patients (half with both migraines and MS- I just go over MS issues at the injection visit) see me every 3 months but may need an additional visit for a trigger point or Toradol if bad migraine occurs in between visit. These would be cut to twice a year if ever approved (or available off label) for migraine. My few cervical dystonia patients would see me only every 5-6 months with the RVNC product instead of 3 months with Botox or Xeomin. Though insurance would initially be an issue (off label), my limb spasticity MS patients would see me one or two fewer visits a year based on duration of Daxi effect. Many patients would be interested in 1-2 fewer injections a year, others would have a 'ain't broke don't fix it attitude'.

[vinmantoo]

I think that for most of these indications patients are going to be seeing their doctor quarterly anyway. So the value proposition here is simply less shots as opposed to fewer doctor visits.

Why in the world would they keep going to visit the doctor if there is no need for, as you put it, a vanity product?